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Letter to the Editor 
 
What next after Fansidar? The question of antimalarial drugs in Ethiopia 
 
   In Ethiopian settings, patients getting the required treatments for malaria complications in 
hospitals would constitute a negligible percentage; malaria in Ethiopia hence, possibly costing 
millions of lives a year based on a 4.1% hospitalization rate (1).  The fatal effects of falciparum 
malaria, however, depends on the local eco-epidemiology and malaria endemicity with its immune 
profile, population density and age structure, health infrastructure and level and rate of drug resistant 
Plasmodium falciparum. At present chloroquine cure rate in Ethiopia is expected in the range of 30-
70% (2,3), in some areas even going below 15% (4).  This has triggered a shift to sulfadoxine-
pyrimethamine S-P, trade marked Fansidar, as a 1st line drug in line with chloroquine (cq). S-P is 
presently considered highly (>95%) efficacious (3,5) in Ethiopia.   
   In Kenya and Malawi where S-P has been used as a  1st line drug as of 1993 -’94, and in Tanzania 
where S-P has been used for over a decade, clinical and parasite clearance failure rate in resistant 
foci has already gone up to 30% (6).  The fate of S-P wouldn’t be different in Ethiopia where it has 
been used for over a decade, as of 1986, as a 2nd line drug, calling forth the timely thought of an 
alternative drug. A combination of quinine (Qn) with antibiotics like tetracycline or doxycycline 
would have been one alternative, had it not been for its limited use excluding the major malaria 
target groups children, i.e, < 8 years old and pregnant women, due to the antibiotics ossification 
effect (6). Moreover, use of Qn for uncomplicated malaria has the risk of compromising its efficacy 
in the treatment of severe and complicated malaria (SCM).   
   The quinine congener mefloquine and the phenanthrine, antimalarial halofantrine are the other 
options. But, besides their alleged cardiac and neuro-toxicity, their price is very high. At around 
5USD per adult dose.  The treatment cost rises nearly 50 times that of Cq, Qn, S-P and amodiaquine 
(Aq), beyond the capacity of a national malaria control program of a country like Ethiopia (7).  Other 
than the last line drugs, the Arthemisinin derivatives, this leaves with two other alternative drugs:  
Amodiaquine and the proguanil-atovaquone combination.  Both are cheap and highly efficacious.  
The latter drug, however, may not be advisable as 2nd line drug presently, as it is in the same 
antifolate drug family as the 1st line drug, S-P due to which there is a possibility of initiating cross 
resistance.  This pushes the proguanil-atovaquone combination to 3rd line drug after amodiaquine.  
This scheme of alternating 4-aminoquinolines with antifolate drugs and reserving quinine for SCM, 
may be a rational use of the present drugs in the therapeutic management of malaria in Ethiopia. 
   The biggest worry with amodiaquine is its adverse effects.  Blood disorders including 
agranulocytosis rate of 0.007% and fatality rate of 0.005% is recorded (6). Presently Aq safety study 
is about to start in Ethiopia, and the risk-benefit in Aq  use is the question that is to be addressed. 
However, in a country where malaria is epidemic with very high death toll, treatment fatality of 
0.005% is not only tolerable, but is also within ethical bound. Especially, in areas where referral is 
difficult and S-P cure rate is less than 98%, the severity of the disease outcomes in S-P non 
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